Sciences of GileadNASDAQ: GOLDEN) shares are trading in the red for the seventh day in a row, falling 0.18% to $76.82 on Wednesday, a day before reporting its fourth-quarter results. The short interest on GILD stands at 1.38% of the total float.
Gilead Sciences is is down 5% year to date, compared to the broader S&P 500, which is up 3.96%. In the last 12 months, the stock is down 11.15%.
Looking at Search Alpha's quantitative ratings, this California-based company has a Strong Buy rating with a score of 4.79 out of 5. When it comes to Wall Street analysis, 15 out of 32 analysts recommend Hold, 11 the rate it as a Strong Buy, 5 rate it as a Buy and 1 recommend a Strong Sell.
Looking Alpha analysts have a Buy rating for the company with a score of 3.71 out of 5.
According to SA analyst Danil Sereda, “Gilead shares look cheap, the business looks healthy and it has a deep pipeline. Additionally, there are signs of a possible earnings improvement in the fourth quarter.”
It's January 22North Dakota, GILD fell more than 10%, the biggest intraday drop in a decade, following disappointing results from its Trodelvy trial for the treatment of lung cancer. Sereda said: “The stock sell-off due to the Trodelvy trial disappointment appears disproportionate, given that the drug represents only ~4.04% of Gilead's total product sales.
Gilead Sciences traded lower after its last quarter earnings, although it reported an improvement in revenue and EPS. It is scheduled to report its fourth-quarter results on Tuesday after markets close, and analysts expect quarterly revenue of $7.1 billion with earnings of $1.76 per share.
